MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers
Anastasia Wyce(GlaxoSmithKline (United States)), Olena Barbash(GlaxoSmithKline (United States)), Daniel Felitsky(Target (United States)), Melissa Stern(Merck & Co., Inc., Rahway, NJ, USA (United States)), Melissa C. Musso(GlaxoSmithKline (United States)), Lijoy K. Mathew(GlaxoSmithKline (India)), Michael T. McCabe(GlaxoSmithKline (United States)), Shawn W. Foley(GlaxoSmithKline (United States)), Natalie O. Karpinich(GlaxoSmithKline (United States)), Jeanne J. Matteo(GlaxoSmithKline (United States)), Satyajit Rajapurkar(GlaxoSmithKline (United States)), Kathryn Keenan(GlaxoSmithKline (United States)), Christopher Carpenter(Beaumont Hospital, Royal Oak), Peter J. Tummino(Intarcia Therapeutics (United States)), Ryan G. Kruger(Arysta LifeScience (France)), Susan Korenchuk(GlaxoSmithKline (United Kingdom)), Xiping Zhang(Fudan University), Charles F. McHugh(GlaxoSmithKline (United States))
Cited by 36
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550